Bristol-Myers (BMY) to terminate Avagacestat clinical developmen
Tweet
Share
E-mailGet Alerts BMY Hot Sheet
Join SI Premium – FREE
Bristol-Myers Squibb Co. (NYSE: BMY) to terminate Avagacestat clinical development, according to Bloomberg headlines.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)
- AbbVie lung cancer drug data shows high response rates at WCLC 2026
- Keenova doses first patient in Phase 3 hammer toe drug trial
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
